Foghorn Therapeutics Inc.
FHTX
$3.87
$0.164.31%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -64.67% | 13.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -64.67% | 13.42% | |||
| Cost of Revenue | -17.18% | 10.22% | |||
| Gross Profit | -17.13% | -8.02% | |||
| SG&A Expenses | -3.18% | 2.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.88% | 8.21% | |||
| Operating Income | -10.09% | -5.92% | |||
| Income Before Tax | 8.26% | -36.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.26% | -36.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.26% | -36.69% | |||
| EBIT | -10.09% | -5.92% | |||
| EBITDA | -13.52% | -6.49% | |||
| EPS Basic | 16.80% | -36.58% | |||
| Normalized Basic EPS | -3.66% | -9.61% | |||
| EPS Diluted | 16.80% | -36.58% | |||
| Normalized Diluted EPS | -3.66% | -9.61% | |||
| Average Basic Shares Outstanding | 10.27% | 0.06% | |||
| Average Diluted Shares Outstanding | 10.27% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||